PMID- 35262170 OWN - NLM STAT- MEDLINE DCOM- 20220620 LR - 20220727 IS - 1945-7197 (Electronic) IS - 0021-972X (Linking) VI - 107 IP - 7 DP - 2022 Jun 16 TI - Growth Hormone and Thyroid Function in Children With Attention Deficit Hyperactivity Disorder Undergoing Drug Therapy. PG - 2047-2056 LID - 10.1210/clinem/dgac139 [doi] AB - CONTEXT: The trends in hormone indices of children with attention deficit hyperactivity disorder (ADHD) who received long-term medication treatment remains controversial. OBJECTIVE: This prospective study aimed to examine the changes in the growth hormone and thyroid hormone systems among children with ADHD undergoing various medication treatments. METHODS: In total, 118 children who were diagnosed with ADHD and were drug-naive were observed naturalistically over 12 months. Of them, 22 did not receive any medication, while 39, 40, and 17 were treated with low doses of short-acting methylphenidate (MPH) (14 +/- 6.7 mg/day), osmotic-release oral system (OROS) long-acting MPH (32 +/- 9.6 mg/day), and atomoxetine (29.2 +/- 9.7 mg/day), respectively. Blood samples were obtained at both the baseline and the endpoint (month 12) to measure serum levels of insulin-like growth factor 1 (IGF-1), IGF binding protein 3 (IGFBP-3), prolactin, thyroid-stimulating hormone (TSH), triiodothyronine (T3), thyroxine (T4), and free T4. RESULTS: Trends for IGF-1, IGFBP-3, prolactin, TSH, T3, T4, and free T4 levels were similar among the 4 groups. Changes in serum levels of IGF-1 were positively correlated with changes in height and weight of all the children with ADHD. However, patients who received MPH treatment had less body weight gain than the nonmedicated group. The ratio of MPH doses to body weight was inversely correlated with the increment in height. CONCLUSION: There were no changes in thyroid or growth hormones associated with the low doses of ADHD medications used in this study within 1 year's duration. Nonetheless, patients' growth and the appropriateness of drug dosage should be closely monitored. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Wang, Liang-Jen AU - Wang LJ AUID- ORCID: 0000-0002-5320-1151 AD - Department of Child and Adolescent Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Huang, Ying-Hua AU - Huang YH AD - Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Chou, Wen-Jiun AU - Chou WJ AD - Department of Child and Adolescent Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. FAU - Lee, Sheng-Yu AU - Lee SY AUID- ORCID: 0000-0001-7796-9643 AD - Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. AD - Department of Psychiatry, College of Medicine, Graduate Institute of Medicine, School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. LA - eng GR - CMRPG8J0361/Chang Gung Memorial Hospital/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - J Clin Endocrinol Metab JT - The Journal of clinical endocrinology and metabolism JID - 0375362 RN - 0 (Central Nervous System Stimulants) RN - 0 (Delayed-Action Preparations) RN - 0 (Insulin-Like Growth Factor Binding Protein 3) RN - 12629-01-5 (Human Growth Hormone) RN - 207ZZ9QZ49 (Methylphenidate) RN - 67763-96-6 (Insulin-Like Growth Factor I) RN - 9002-62-4 (Prolactin) RN - 9002-71-5 (Thyrotropin) SB - IM MH - *Attention Deficit Disorder with Hyperactivity/drug therapy MH - Body Weight MH - *Central Nervous System Stimulants/therapeutic use MH - Child MH - Delayed-Action Preparations/therapeutic use MH - *Human Growth Hormone/blood MH - Humans MH - Insulin-Like Growth Factor Binding Protein 3/blood MH - Insulin-Like Growth Factor I/analysis MH - *Methylphenidate/therapeutic use MH - Prolactin MH - Prospective Studies MH - *Thyroid Gland MH - Thyrotropin/blood MH - Treatment Outcome OTO - NOTNLM OT - ADHD OT - endocrinology OT - growth hormones OT - prospective study OT - stimulants OT - thyroid EDAT- 2022/03/10 06:00 MHDA- 2022/06/22 06:00 CRDT- 2022/03/09 08:45 PHST- 2021/12/09 00:00 [received] PHST- 2022/03/10 06:00 [pubmed] PHST- 2022/06/22 06:00 [medline] PHST- 2022/03/09 08:45 [entrez] AID - 6545254 [pii] AID - 10.1210/clinem/dgac139 [doi] PST - ppublish SO - J Clin Endocrinol Metab. 2022 Jun 16;107(7):2047-2056. doi: 10.1210/clinem/dgac139.